Lysando AG

TRIESENBERG, Liechtenstein--(BUSINESS WIRE)-- Lysando, leading biotech in antimicrobial proteins, proudly announces the addition of Mr. Jorge Cortell to its esteemed Advisory Board marking a significant milestone in the company's growth. As a serial entrepreneur and renowned visionary in healthcare technology he brings a wealth of expertise to Lysando's strategic direction. This press release features multimedia. View the full release here: Jorge Cortell - Advisory Board Member Lysando AG As Senior Advisor for Healthcare and Life Sciences at Harvard University Innovation Laboratories, and a technology advisor to NLC, Europe's largest HealthTech Venture Builder, Jorge Cortell's background positions him as a thought leader in the global industry. His profound understanding of both tech and business landscapes makes him an asset in guiding Lysando towards new heights of success. “At Lysando, our mission is helping patients rather than simply selling treatments. Antibiotic resistance is estimated to claim over a million lives annually worldwide, posing an existential threat to society. Moreover, contamination of our environment by pharmaceuticals, particularly antibiotics, poses an alarming additional danger,” says Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando AG. “With our Artilysin® technology, we are committed to combating resistance, promoting green pharma practices, and envisioning a future without fear of bacterial infections. As time is of the essence, we are delighted to have Jorge on board; a visionary who embodies innovation, comprehends AI, and supports Lysando's endeavour to save millions from pathogenic bacteria.” “I am delighted to announce my appointment to the Advisory Board of this pioneer in the field of innovative antimicrobial solutions,” says Jorge Cortell, newly appointed Advisory Board member of Lysando AG. “Joining Lysando represents an exciting opportunity to contribute my expertise in cutting-edge technologies and their potential to revolutionize healthcare. I believe in Lysando's mission to address the global challenge of antimicrobial resistance and to improve patient outcomes through transformative therapeutic solutions. Together, we will strive to shape a healthier future by harnessing the power of science and innovation.” Jorge Cortell's involvement on the Advisory Board promises to drive the company's mission, ultimately ushering in a future of improved quality of life for all. About Lysando AG Lysando is market leader for antimicrobial proteins, so‐called Artilysin® molecules. They can effectively eliminate problem‐causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin® constitutes an innovative, proprietary, and environmentally friendly technology with a wide range of applications. View source version on businesswire.com: Contacts Verena Schossmann +41(0)79 211 83 42 Verena.Schossmann@lysando.com Source: Lysando Smart Multimedia Gallery Photo Jorge Cortell - Advisory Board Member Lysando AG Logo View this news release and multimedia online at:

Heading up AiCuris’ refocused pipeline will be Pritelivir, which is in phase 3 development to treat acyclovir-resistant herpes simplex virus infections. AiCuris is doubling down on its infectious disease pipeline at the expense of its COVID-19 and foot infection programs. “Sharpening its strategic focus” on a portfolio of therapies for infectious diseases in immunocompromised patients means the biotech will be able to accelerate development plans and prepare for market launch, the Wuppertal, Germany-based company said in a July 6 release. The knock-on effect is that AiCuris “will discontinue research activities outside of this strategic scope.” While the company didn’t go into details of what activities will be scrapped, the COVID-19 therapy AIC649 was notable for its absence from today’s release. The company received 5.9 million EUR ($6.4 million) in funding from a regional German government last year to advance the immune modulator as a potential way to slow progression of COVID-19. The therapy had been undergoing a clinical study in Germany and Africa. Another program that wasn’t name-checked today was AiCuris’ collaboration with fellow German biotech Lysando. The two companies were working on Artilysin, a potential treatment for infected, chronic wounds such as diabetic foot infections. “Unfortunately, anti-infective treatment options for this growing patient population are often limited and few companies are focusing on developing appropriate therapeutic candidates,” AiCuris CEO Larry Edwards said in the release. “This strategic change will allow us to be more efficient and effective from an operations perspective and ensure we are able to bring novel treatment options to patients in need.” Heading up AiCuris’ refocused pipeline will be Pritelivir, which is in phase 3 development to treat acyclovir-resistant herpes simplex virus infections in immunocompromised patients. Topline data is due at the end of 2024. Then there’s AIC468, an anti-sense RNA therapy due to enter the clinic early next year to prevent BK virus infection in kidney transplanted patients. The biotech is also working on preclinical programs designed to combat human adenovirus infections, with a key goal being to develop the first topical treatment specifically designed for ADV infections of the eye.

TRIESENBERG, Liechtenstein--( BUSINESS WIRE )--Amicogen, a leading biotech company specializing in industrial enzyme production and drug development, has partnered with Lysando, an innovative biotech company with expertise in the development of antimicrobial Artilysin ® , to address the rising issue of mastitis in dairy cows caused by multi-resistant bacteria. According to recent research, the overuse of antibiotics in animal husbandry has been driving a fast increase in multidrug-resistant pathogens. Approximately 70% of all antibiotics produced globally are used in agriculture, often as preventative measures, which has accelerated the spread of resistances. Mastitis – a bacterial infection of the udder caused by various, often multi-resistant strains of bacteria – is rapidly spreading, particularly in Asia. This leads to animal suffering and significant wastage of milk production, causing the global dairy industry about $20-30 billion in annual revenue loss. The partnership between Amicogen and Lysando aims to develop an innovative solution to this pressing issue. By leveraging their combined expertise, the companies set out to generate a treatment that is both effective and sustainable, reducing the economic impact of mastitis on farmers while improving animal welfare. “We are excited to partner with Lysando to develop a novel and innovative solution against mastitis in dairy cows,” said Dr. Park, CEO of Amicogen. “This collaboration highlights the growing importance of joining forces in biotech and the potential for innovation to address critical challenges – also in agriculture.” “Our Artilysin ® technology has shown great promise in addressing bacterial infections and we believe that this partnership will make a real difference in the fight against mastitis”, added Dr. Kerstin Emmrich, Director R&D, Lysando AG. The joint effort between Amicogen and Lysando represents a significant step towards combatting the rising problem of antibiotic resistance and improving animal health. The companies envisage to continue their research to deliver innovative solutions for critical challenges. About Amicogen Amicogen Inc (092040.KQ) is a CDMO and biotechnology company based in Jinju, South Korea. Amicogen is a leader in the development and production of specialty enzymes and proteins for the biopharmaceutical, food, cosmetics and other industries. About Lysando Lysando AG is market leader for antimicrobial proteins, so‐called Artilysin ® molecules. They can effectively eliminate problem‐causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin ® constitutes an innovative, proprietary, and environmentally friendly technology with a wide range of applications.